Caiyun Nie

State Key Laboratory Of Metabolic Dysregulation & Prevention And Treatment Of Esophageal Cancer
Zhengzhou, 450052, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer.

Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer.

Journal: Gastroenterology report

Published: December 19, 2025

Single-arm, open-label, multicentre phase 1b/2 study to evaluate the safety and efficacy of fruquintinib combined with sintilimab and CAPEOX as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (FUNCTION study): a study protocol.

Single-arm, open-label, multicentre phase 1b/2 study to evaluate the safety and efficacy of fruquintinib combined with sintilimab and CAPEOX as a first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (FUNCTION study): a study protocol.

Journal: BMJ open

Published: September 26, 2025

APLN, a novel prognostic biomarker, contributes to esophageal carcinoma development.

APLN, a novel prognostic biomarker, contributes to esophageal carcinoma development.

Journal: Functional & integrative genomics

Published: September 11, 2025

Identification of molecular subtypes based on pseudouridine modification in hepatocellular carcinoma.

Identification of molecular subtypes based on pseudouridine modification in hepatocellular carcinoma.

Journal: Cancer cell international

Published: February 01, 2025

Circulating DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer.

Circulating DNA methylation-based diagnostic, prognostic, and predictive biomarkers in colorectal cancer.

Journal: Scientific reports

Published: January 03, 2025

Efficacy and prognostic factors of PD-1 inhibitors combined with apatinib in advanced diffuse gastric cancer.

Efficacy and prognostic factors of PD-1 inhibitors combined with apatinib in advanced diffuse gastric cancer.

Journal: Neoplasma

Published: October 21, 2024

Gastric cancer patient with MET amplification treated with crizotinib achieves long-term survival: a case report.

Gastric cancer patient with MET amplification treated with crizotinib achieves long-term survival: a case report.

Journal: AME case reports

Published: May 24, 2024

Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer.

Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer.

Journal: Technology in cancer research & treatment

Published: March 18, 2024

Novel GSH-responsive prodrugs derived from indole-chalcone and camptothecin trigger apoptosis and autophagy in colon cancer.

Novel GSH-responsive prodrugs derived from indole-chalcone and camptothecin trigger apoptosis and autophagy in colon cancer.

Journal: Bioorganic chemistry

Published: November 07, 2023

In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.

In era of immunotherapy: the value of trastuzumab beyond progression in patients with trastuzumab-resistant HER2-positive advanced or metastatic gastric cancer.

Journal: Therapeutic advances in gastroenterology

Published: October 19, 2023

Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.

Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study.

Journal: BMC cancer

Published: September 27, 2023

Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.

Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.

Journal: Cancer medicine

Published: July 31, 2023

Showing 1-12 of 37

Last Updated: 09/26/2026